Google
Trusted Resources: News & Events
Latest announcements and gatherings
GlycoMimetics Announces Pricing of Public Offering of Common Stock
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $11.50 per share. The gross proceeds from the offering are expected to be $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by GlycoMimetics. The offering is expected to close on or about May 30, 2017, subject to customary closing conditions.
Jefferies LLC and Cowen are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. is acting as lead manager for the offering. GlycoMimetics has granted to the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount.
+myBinderRelated Content
-
Sickle Cell Program at UI HealthThe Sickle Cell Program at UI Health is ...
-
Gene-Edited ‘Supercells’ Make Progress In Fight Against Sickle Cell DiseaseDoctors are reporting the first evidence...
-
Clint Joiner, MD, PhDDr. Clinton Joiner is a Director of Hema...
-
Elizabeth S. Klings, MDDr. Klings is an Associate Professor in ...
-
Sensorineural Hearing Loss in Children With Sickle Cell DiseaseIntroduction: Sensorineural hearing los...
-
University of Illinois at Chicago awarded $4.6 million NIH grant for chronic pain researchThe University of Illinois at Chicago ha...
-
Dyspareunia is Associated With Chronic Pain in Premenopausal Women With Sickle Cell DiseaseObjectives: Pain is common in women wit...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.